Located in Boston and the surrounding communities, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
GENERAL SUMMARY: The Associate Director for Medical Review (ADMR) is a member of the senior management of the Office for Human Research Studies (OHRS).
OHRS is responsible for the management of scientific review (SRC), institutional review board review (IRB) and Health Insurance Portability and Accountability Act (HIPAA) review of all cancer related research involving human subjects conducted by the clinical institutions that make up the Dana-Farber/Harvard Cancer Center including: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Massachusetts General Hospital and the Beth Israel Deaconess Medical Center
OHRS receives approximately 700 new protocols a year; 4000+ amendments; 1650+ continuing reviews, 2000+ deviations, violations and eligibility exceptions as well as about 1500+ serious adverse events. OHRS manages six scientific review committees and seven institutional review boards.
The primary responsibility of the ADMR is to manage the scientific review process and ensure that the various committees are conducting consistent reviews. In addition, the ADMR works with the chairs of the committees and the members to identify issues that impact scientific merit, feasibility of the research and prioritization and work towards the creation of policies, procedures and practices that will ensure a robust scientific review process.
The ADMR also serves as a member of all seven institutional review boards and works to ensure consistency between scientific review and IRB review of research protocols.
The ADMR supervises the Human Research Coordinators who are responsible for SRC minutes; participates in the general management of the office; and is integral to the creation, maintenance and evolution of the various systems, policies and procedures that support the work of the OHRS.
The ADMR may review research protocols that are submitted to OHRS, including amendments, eligibility exceptions, deviations, violations as well as serious adverse events and conduct initial medical review in anticipation of scientific review or institutional review board review.
The ADMR participates in meetings with Senior Officials of all of the Dana-Farber/Harvard Cancer Center on issues relating to the review, approval and oversight of cancer research involving human subjects. The ADMR also serves as a liaison to study teams in that the ADMR communicates with study teams after scientific review committee meetings and meets with study teams in order to assist in improving the quality of protocol submissions.
The ADMR is also responsible for working together collaboratively with the other OHRS senior staff in managing situations involving non-compliance; subject complaints; AAHRPP accreditation; HHS and FDA IRB audits; FDA audits of investigators; and other similar regulatory and substantive activities.
PRIMARY DUTIES AND RESPONSIBILITIES:
MINIMUM JOB QUALIFICATIONS:
KNOWLEDGE, SKILLS, AND ABILITIES REQUIRED:
This is a position that involves working in an office; at a computer; on the phone, etc. Regular travel to Main Campus from Fenway/Brookline Village Area (0.5 – 0.8 miles each way) is required. A free shuttle bus is available between these locations.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.